Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
Clinical Trials
52
Active:9
Completed:11
Trial Phases
4 Phases
Phase 1:32
Phase 2:14
Phase 3:5
+1 more phases
Drug Approvals
2
PHILIPPINES:2
Clinical Trials
Distribution across different clinical trial phases (52 trials with phase data)• Click on a phase to view related trials
Phase 1
32 (61.5%)Phase 2
14 (26.9%)Phase 3
5 (9.6%)Not Applicable
1 (1.9%)Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Not Applicable
Not yet recruiting
- Conditions
- Patients With Advanced or Metastatic Malignant Tumors
- Interventions
- Drug: SHR-1501, Adebrelimab
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 203
- Registration Number
- NCT07073534
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Adebelimab InjectionDrug: Ametinib Mesylate Tablets
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06895928
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Phase 1
Active, not recruiting
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: [14C] SHR6508 Injection
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT06877247
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, Shandong, China
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Phase 3
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06738251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06704828
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found